Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery
Authors:
- 1 August 2020
- journal article
- review article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 200, 112426
Abstract
No abstract availableKeywords
This publication has 91 references indexed in Scilit:
- Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteinsProceedings of the National Academy of Sciences, 2012
- Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding SitesJournal of Medicinal Chemistry, 2012
- Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain FamilyCell, 2012
- Structural basis for recognition of H3K56-acetylated histone H3–H4 by the chaperone Rtt106Nature, 2012
- Bromodomain protein Brd3 associates with acetylated GATA1 to promote its chromatin occupancy at erythroid target genesProceedings of the National Academy of Sciences, 2011
- Regulation of chromatin by histone modificationsCell Research, 2011
- Mechanism and regulation of acetylated histone binding by the tandem PHD finger of DPF3bNature, 2010
- Brd4 Marks Select Genes on Mitotic Chromatin and Directs Postmitotic TranscriptionMolecular Biology of the Cell, 2009
- Structures of the Dual Bromodomains of the P-TEFb-activating Protein Brd4 at Atomic ResolutionJournal of Biological Chemistry, 2009
- The language of covalent histone modificationsNature, 2000